Exenatide and glucagon co-infusion increases myocardial glucose uptake and improves markers of diastolic dysfunction in adults with type 2 diabetes

Exenatide and glucagon co-infusion increases myocardial glucose uptake and improves markers of diastolic dysfunction in adults with type 2 diabetes

Abstract Type 2 diabetes (T2D) significantly increases the risk of heart failure, a major cause of hospitalisation and increased morbidity and mortality. Dual and multi-agonist synthetic peptides at the GLP-1 and glucagon receptor are in clinical development as potential new treatments for a range o...

Full description

Saved in:
Bibliographic Details
Main Authors: James Goodman, Martin Schain, Giovanni Di Stefano, Victoria Lupson, Tracy Horn, Marion Hill, Roie Manavaki, Timothy D. Fryer, Elaine Bumanlag-Amis, Navazh Jalaludeen, Lutz Jermutus, Edvin Johansson, Kerstin Heurling, Henrik Haraldsson, Mark Evans, Joseph Cheriyan, Lars Johansson, Philip Ambery, Ian B. Wilkinson
Format: Article
Language:English
Published: Nature Portfolio 2025-07-01
Series:Scientific Reports
Subjects:
GLP-1
Glucagon
GLP-1/glucagon
Dual-agonism
Myocardial glucose uptake
18F-FDG
Online Access:https://doi.org/10.1038/s41598-025-04559-3
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1038/s41598-025-04559-3

Similar Items